bat365官网登录入口

院长论坛

报告题目：Self-assembled aptamer-nanomedicine for precision cancer therapy

报告人：Youli Zu, MD, PhD

                Department of Pathology and Laboratory Medicine

                Weill Cornell Medical College of Cornell University

                Endowed Chair in Pathology

                Director of Hematopathology Section

                Department of Pathology and Genomic Medicine

                Houston Methodist Hospital

时    间：2018 年10 月22 日（星期一）下午2:00-4:00

地    点：中心楼502会议室

主持人：邱晓彦教授

报告人简介：

Dr. Zu is the director of Hematopathology Section, Department of Pathology and Genomic Medicine, Houston Methodist Hospital. In addition to clinical service, Dr. Zu is also conducting translational research. His lab has pioneered aptamer technology development and been interested in applying oligonucleotide aptamers to disease diagnosis and precision cancer therapy.

Representative Publications:

1. Wang X, et.al, ZY, Young KH.Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.Neoplasia. 2018 Jun;20(6):574-593. 

2. Zhao N, Zeng Z, Zu Y. Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.Small. 2018 Jan;14(4).

3. Wen J, Tao W, Hao S, Zu Y. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.J Hematol Oncol. 2017 Jun 13;10(1):119. 

4. Li H, Yang S, Yu G, Shen L, Fan J, Xu L, Zhang H, Zhao N, Zeng Z, Hu T, Wen J, Zu Y. Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy.Theranostics. 2017 Mar 6;7(5):1204-1213. 

5. Sun H, Tan W, Zu Y. Aptamers: versatile molecular recognition probes for cancer detection.Analyst. 2016 Jan 21;141(2):403-15.

6.Zhao N, Pei SN, Qi J, Zeng Z, Iyer SP, Lin P, Tung CH, Zu Y.Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Biomaterials. 2015 Oct;67:42-51.

 

 

 

欢迎师生参加！